Izrael - angličtina - Ministry of Health

taro international ltd, israel - etoricoxib - film coated tablets - etoricoxib 30 mg - etoricoxib - indicated for the symptomatic relief of osteoarthritis (oa).

Izrael - angličtina - Ministry of Health

taro international ltd, israel - etoricoxib - film coated tablets - etoricoxib 60 mg - etoricoxib - indicated for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra) and ankylosing spondylitis.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - etoricoxib - film coated tablets - etoricoxib 90 mg - etoricoxib - indicated for the symptomatic relief of rheumatoid arthritis (ra) and ankylosing spondylitis.for the short-term treatment of moderate pain associated with dental surgery.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - sevelamer carbonate anhydrous - powder for suspension - sevelamer carbonate anhydrous 2.4 g - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l. should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimethyl fumarate - dimethyl fumarate taro is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 240 mg - dimethyl fumarate - dimethyl fumarate taro is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - deferasirox - dispersible tablets for oral suspension - deferasirox 125 mg - deferasirox - deferasirox taro is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox taro is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic]≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). lic is the preferred method of iron overload determination and should be used wherever available.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - deferasirox - dispersible tablets for oral suspension - deferasirox 250 mg - deferasirox - deferasirox taro is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox taro is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic]≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). lic is the preferred method of iron overload determination and should be used wherever available.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - deferasirox - dispersible tablets for oral suspension - deferasirox 500 mg - deferasirox - deferasirox taro is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox taro is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic]≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). lic is the preferred method of iron overload determination and should be used wherever available.

Izrael - angličtina - Ministry of Health

taro international ltd, israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - primary hypercholesterolemia: ezetimibe taro administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetimibe taro administered with a statin are indicated for use in patients with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis). homozygous sitosterolemia (phytosterolemia): ezetimibe taro are indicated for use in patients with homozygous familial sitosterolemia.